NASDAQ$MGNX
MacroGenics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
MacroGenics reported first quarter 2024 financial results and provided an update on corporate progress and interim TAMARACK Phase 2 study data.
MacroGenics reported a total revenue of $9.1 million for the quarter ended March 31, 2024, compared to $24.5 million for the quarter ended March 31, 2023. Net loss was $52.2 million for the quarter ended March 31, 2024, compared to net loss of $38.0 million for the quarter ended March 31, 2023. Cash, cash equivalents and marketable securities were $184.2 million as of March 31, 2024.
- Presented interim TAMARACK Phase 2 study data with updated safety and preliminary efficacy of vobra duo in mCRPC patients.
- Initiated planning activities for a potential Phase 3 study of vobra duo, which could commence next year.
- Completed enrollment of the TAMARACK Phase 2 study of vobra duo in November 2023.
- Plans to expand the TAMARACK study of vobra duo by enrolling patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN) and anal cancer, with dosing expected to begin in mid-2024.
Headline financials
Revenue & EPS history
MacroGenics · Revenue · Quarterly
$9.1M
Revenue by segment
MacroGenics · $9.5M total across 3 segments · Q3 2023
- Product Sales$4.7M—49.4%
- Contract Manufacturing$4.46M+290.7%47.0%
- Government Agreements$345K-36.9%3.6%
Forward guidance
MacroGenics anticipates its cash, cash equivalents and marketable securities balance of $184.2 million as of March 31, 2024, in addition to projected and anticipated future payments from partners and product revenues should extend its cash runway into 2026.
Tailwinds
- Cash runway extends into 2026.
- Phase 2 TAMARACK clinical trial expenditures are anticipated.
- Phase 2 LORIKEET study expenditures are anticipated.
- Ongoing clinical and preclinical studies expenditures are anticipated.
- Future payments from partners are anticipated.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
+5.6%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+3.4%
Avg return
30 days after
44%
23 / 52 earnings
Positive
+251.7%
Q1 2020
Best reaction
-77.4%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.9% | +24.0% | +12.9% | |
| Q4 2025 | +45.3% | +27.1% | +45.8% | |
| Q3 2025 | +8.3% | +4.8% | -4.8% | |
| Q1 2025 | +0.0% | +0.0% | -5.1% | |
| Q4 2024 | -4.8% | -25.7% | -40.0% | |
| Q3 2024 | +13.2% | +17.6% | -8.4% | |
| Q2 2024 | -5.6% | -1.7% | -5.6% | |
| Q1 2024 | -77.4% | -69.6% | -69.1% | |
| Q4 2023 | -18.8% | -18.0% | -15.0% | |
| Q3 2023 | +20.0% | +20.5% | +62.7% | |
| Q2 2023 | +26.6% | +13.7% | +4.7% | |
| Q1 2023 | -0.4% | -9.1% | -28.2% | |
| Q4 2022 | +8.4% | +3.7% | +0.6% | |
| Q3 2022 | +22.1% | +30.1% | +42.3% | |
| Q2 2022 | +16.2% | +18.9% | -3.6% | |
| Q1 2022 | -15.2% | -38.2% | -56.5% | |
| Q4 2021 | -3.6% | -8.1% | -12.7% | |
| Q3 2021 | +4.1% | +5.1% | -16.7% | |
| Q2 2021 | -5.5% | -5.7% | -10.3% | |
| Q1 2021 | -8.3% | -9.8% | -8.8% | |
| Q4 2020 | +18.7% | +16.1% | +57.6% | |
| Q3 2020 | +4.9% | +0.9% | +19.9% | |
| Q2 2020 | -1.5% | +3.1% | +5.9% | |
| Q1 2020 | +251.7% | +184.5% | +186.4% | |
| Q4 2019 | +8.5% | -20.8% | -45.5% | |
| Q3 2019 | -0.9% | -6.5% | +13.9% | |
| Q2 2019 | -0.3% | -9.1% | -2.5% | |
| Q1 2019 | +3.4% | +9.7% | +9.4% | |
| Q4 2018 | -2.8% | -5.8% | -19.4% | |
| Q3 2018 | +8.7% | -1.0% | -2.3% | |
| Q2 2018 | +6.3% | +9.5% | +11.1% | |
| Q1 2018 | -9.2% | -7.8% | +2.8% | |
| Q4 2017 | +2.1% | +17.7% | +2.4% | |
| Q3 2017 | -1.6% | -0.3% | +8.9% | |
| Q2 2017 | +6.6% | +8.0% | +17.8% | |
| Q1 2017 | -1.7% | -12.2% | -9.9% | |
| Q4 2016 | -5.1% | -2.7% | -15.8% | |
| Q3 2016 | -16.3% | -6.0% | +10.4% | |
| Q2 2016 | +6.8% | +1.1% | -2.2% | |
| Q1 2016 | -5.8% | — | — | |
| Q4 2015 | +5.1% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | -12.1% | — | — | |
| Q1 2015 | +9.5% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | +17.5% | — | — | |
| Q2 2014 | -4.8% | — | — | |
| Q2 2013 | -4.8% | — | — | |
| Q1 2014 | -5.0% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2013 | -7.6% | — | — | |
| Q3 2013 | +7.3% | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro